Australia markets closed

Chimerix, Inc. (CMRX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.9380-0.0042 (-0.45%)
At close: 04:00PM EDT
0.9499 +0.01 (+1.27%)
After hours: 05:51PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.9422
Open0.9300
Bid0.9064 x 100
Ask0.9420 x 200
Day's range0.9251 - 0.9422
52-week range0.8800 - 1.5700
Volume271,608
Avg. volume339,782
Market cap84.073M
Beta (5Y monthly)1.12
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update

    – Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No Dose Limiting Toxicity in ONC206 Phase 1 Studies to Date, Preliminary Phase 1 Safety and Pharmacokinetic (PK) Data Expected This Summer – – Company to Advance Dordaviprone in Provisional Registration Process Following Positive Interaction with Therapeutic Goods Administration (TGA) in Australia – – Conference Call at 8:30 a.m. ET Today – DURHAM

  • GlobeNewswire

    Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024

    DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Wednesday, May 1, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business overview. To access the live conference call, please dial (646)

  • GlobeNewswire

    Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    DURHAM, N.C., April 16, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that on April 10, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement awards to four new employees of non-statutory stock options to purchase up to a total of 223,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing rule